A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

Clinical trial NCT06948994 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06948994
Sponsor: Guangzhou Women and Children's Medical Center
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuroblastoma GD2 Antibody Autologous NK Cell

Start date: 2025-05-01
Primary completion: 2027-04-30
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.